Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridium chauvoei is a Gram-positive, anaerobic, spore-forming bacterium that is the primary causative agent of blackleg (also known as black quarter), a highly fatal myonecrosis in cattle and other ruminants (Frey et al., 2012; VetBact.org). The organism persists in the environment as resilient spores that can remain latent in animal tissues until triggered by anaerobic conditions, such as muscle trauma (Uzal, 2012; OSU.edu). Upon germination, the vegetative bacteria produce several potent toxins, most notably Clostridium chauvoei toxin A (CctA), a beta-barrel pore-forming toxin that is the major virulence factor responsible for tissue destruction and systemic toxemia (Frey et al., 2012; Nicholson et al., 2019). Other virulence factors include sialidases (NanA), hyaluronidases, and DNases, which contribute to the disorganization of muscle tissue (Vilei et al., 2011; Falquet et al., 2013). While antibiotics like penicillin and gentamicin can be effective in vitro, the rapid progression of the disease often makes clinical treatment futile, leading to death within 24 to 48 hours (Banglajol.info; SkyVetPharm.com). Consequently, control relies heavily on prophylactic vaccination with bacterin-toxoids that induce neutralizing antibodies against CctA and other cellular antigens (Nicholson et al., 2019; ResearchGate.net).
Antibiotics such as penicillin inhibit bacterial cell wall synthesis, while gentamicin inhibits protein synthesis; vaccines primarily target the CctA toxin to neutralize its pore-forming activity (Nicholson et al., 2019; Banglajol.info).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridium chauvoei (C. chauvoei).